Why PuraPly™ Antimicrobial?

It is estimated that biofilm, the polymeric film that makes it difficult to eliminate pathogens,1 is present in 60% of chronic wounds.2 Topical antimicrobials, such as some silver preparations, have demonstrated cytotoxic effects associated with delayed healing,3,4 whereas PuraPly Antimicrobial utilizes PHMB,5 a noncytotoxic antimicrobial substance known to inhibit the formation of biofilm on the wound surface.6

Learn more about the benefits of collagen and PHMB here.

PuraPly Antimicrobial Demonstrated Greater Reduction in MRSA vs Other Products7

Porcine study
In a preclinical study, PuraPly Antimicrobial reduced MRSA up to 47% more than other silver preparations at 72 hours.7  Learn more.

References: 1. Mulder GD, Cavorsi JP, Lee DK. Wounds. 2007;19(7):173-182. 2. Wolcott R, Cutting KF, Ruiz JC. Association for the Advancement of Wound Care. Publication No. UKCT-A0021. 2008:12-17. 3. Zou SB, Yoon WY, Han SK, Jeong SH, Cui ZJ, Kim WK. Int Wound J. 2013;10(3):306-312. 4. Storm-Versloot MN, Vos CG, Ubbink DT, Vermeulen H. Cochrane Database Syst Rev. 2010;(3):CD006478. 5. PuraPly Antimicrobial [package insert]. Canton, MA: Organogenesis, Inc; 2015. 6. Hübner NO, Kramer A. Skin Pharmacol Physiol. 2010;23(suppl):17-27. 7. Data on file. Organogenesis, Inc.